ACTIONS OF RITANSERIN, A 5-HT2/1C ANTAGONIST, IN BENZODIAZEPINE-DEPENDENT RATS

被引:0
|
作者
GOUDIE, AJ
LEATHLEY, MJ
机构
来源
BEHAVIOURAL PHARMACOLOGY | 1993年 / 4卷 / 03期
关键词
ANOREXIA; ANXIOLYTICS; BENZODIAZEPINES; DEPENDENCE; 5-HT2; RECEPTORS; HYPODIPSIA; RATS; RITANSERIN; WEIGHT LOSS; WITHDRAWAL;
D O I
暂无
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The effects of ritanserin on spontaneous benzodiazepine (BZ) withdrawal-induced weight loss, anorexia and hypodipsia were studied. Groups of female rats initially received i.p. injections b.i.d. (11.00 and 17.00 h) of either saline or chlordiazepoxide (CDP). CDP doses increased by 2 mg/kg/day from 10 mg/kg to a final dose of 30 mg/kg. Treatment was maintained for 26 days. Over the next 6 days animals were either treated b.i.d. with vehicle, CDP, or ritanserin at one of three doses (0.16,0.63 and 2.5 mg/kg). In CDP-pretreated animals subsequently treated with vehicle, significant weight loss, anorexia and hypodipsia were seen, relative to controls. In saline-pretreated animals ritanserin had no effect on body weight. However, CDP withdrawal-induced weight loss was actually exacerbated by ritanserin, in a dose-related fashion. Thus, ritanserin potentiated withdrawal-induced weight loss, by a process which did not involve functional (additive) effects of withdrawal and ritanserin treatment. Ritanserin stimulated food intake in saline-pretreated animals. Despite this effect it failed to alleviate CDP withdrawal-induced anorexia. However, in contrast to the weight loss index, no evidence was obtained for potentiation of withdrawal-induced anorexia. In saline-pretreated animals ritanserin had no effect on water intake, nor did it alleviate or potentiate CDP withdrawal-induced hypodipsia. Thus the effects of ritanserin on somatic BZ withdrawal signs depended upon the specific sign studied, different signs showing potentiation or no effect. However, for none of the signs studied was there any evidence that ritanserin alleviated the effect of CDP withdrawal. 5-HT2/1C antagonists may therefore be of limited value in the treatment of somatic aspects of the BZ withdrawal syndrome. They may even exacerbate some BZ withdrawal signs, although a full characterization of the effects of such drugs on BZ withdrawal requires that a number of other different withdrawal signs and symptoms should be studied, since it seems likely that different BZ withdrawal signs involve different underlying mechanisms.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 50 条
  • [31] Effects of the 5-HT2 receptor antagonist ritanserin on halothane-induced increase of inositol phosphates in porcine malignant hyperthermia
    Richter, A
    Scholz, J
    Loscher, W
    Tonner, PH
    Wappler, F
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (05) : 593 - 597
  • [32] A NEW 5-HT2 ANTAGONIST (RITANSERIN) IN THE TREATMENT OF CHRONIC HEADACHE WITH DEPRESSION - A DOUBLE-BLIND-STUDY VS AMITRIPTYLINE
    NAPPI, G
    SANDRINI, G
    GRANELLA, F
    RUIZ, L
    CERUTTI, G
    FACCHINETTI, F
    BLANDINI, F
    MANZONI, GC
    HEADACHE, 1990, 30 (07): : 439 - 444
  • [33] ALLOSTERIC PROPERTIES OF THE 5-HT2 RECEPTOR SYSTEM OF THE RAT TAIL ARTERY - RITANSERIN AND METHYSERGIDE ARE NOT COMPETITIVE 5-HT2 RECEPTOR ANTAGONISTS BUT ALLOSTERIC MODULATORS
    FRENKEN, M
    KAUMANN, AJ
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1987, 335 (04) : 359 - 366
  • [34] ICI-169,369, A 5-HT(2) 5-HT(1C) ANTAGONIST, THAT CAN EVOKE ENDOTHELIUM-DEPENDENT RELAXATION IN RABBIT AORTA
    PIRES, JGP
    RAMAGE, AG
    JACOBS, M
    JOURNAL OF AUTONOMIC PHARMACOLOGY, 1993, 13 (04): : 249 - 255
  • [35] CARDIOVASCULAR AND RENAL ACTIONS OF AHR-16303B, AN ANTAGONIST OF 5-HT2 RECEPTORS AND CALCIUM CHANNELS, IN HYPERTENSIVE AND NORMOTENSIVE RATS
    BARRETT, RJ
    WRIGHT, KF
    ALLEN, AD
    TAYLOR, DR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (01) : 134 - 144
  • [36] A newly synthesized 5-HT2 receptor antagonist, AT-1015, slowly dissociates from 5-HT2 receptors
    Rashid, M
    Nagatomo, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 210P - 210P
  • [37] KETANSERIN - A SELECTIVE ANTAGONIST OF 5-HT2 SEROTONINERGIC RECEPTORS
    VANNUETEN, JM
    LEYSEN, JE
    SCHUURKES, JAJ
    VANHOUTTE, PM
    LANCET, 1983, 1 (8319): : 297 - 298
  • [38] Quetiapine demonstrates functional 5-HT2 antagonist properties
    Goldstein, JM
    Sutton, EB
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 93S - 93S
  • [39] 5-HT2 ANTAGONIST ACTIVITY OF 3-AMINOMETHYLTETRALONES
    LOZA, M
    VERDE, I
    CASTRO, ME
    ORALLO, F
    FONTENLA, JA
    CALLEJA, JM
    RAVINA, E
    CORTIZO, L
    DECEBALLOS, ML
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (12) : 717 - 720